Safety and response after peptide receptor radionuclide therapy with <sup>177</sup>Lu‐DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial

Atsushi Kudo(Tokyo Medical and Dental University), Seigo Kinuya(Kanazawa University Hospital), Kota Yokoyama(Tokyo Medical and Dental University), Makoto Hosono, Daisuke Utsunomiya(Yokohama City University), Noritoshi Kobayashi, Yasushi Ichikawa(Yokohama City University), Ryoichi Yoshimura(Tokyo Medical and Dental University), Shoko Takano(Yokohama City University), Masaharu Hata(Yokohama City University), Minoru Tanabe(Tokyo Institute of Technology), Junichi Tsuchiya(Tokyo Medical and Dental University), Ukihide Tateishi(Tokyo Medical and Dental University)
Journal of Hepato-Biliary-Pancreatic Sciences
December 15, 2021
Cited by 19


Related Papers